

DAFTAR PUSTAKA

1. Harrison TR, Resnick WR, Wintrobe MM, Thorn GW, Adams RD, Beeson PB et al. Harrison's : principles of internal medicine 19th ed. Mc Graw Hill. 2015; 153: 803—13.
2. Global Burden Disease. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016; 388: 1459—544.
3. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramiey AM et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 2015; 373: 415—27.
4. Torres A, Peetermans WE, Viegli G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax*. 2013; 68: 1057—65.
5. Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R et al. High incidence of community-acquired pneumonia among rapidly aging population in japan: a prospective hospital-based surveillance. *Jpn J Infect Dis*. 2014; 67: 269—75.
6. Badan Penelitian dan Pengembangan Kesehatan. Riset kesehatan dasar (RISKESDAS). *Lap Nas* 2018: 1—38.
7. Metlay JP, Waterer P, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community acquired pneumonia : an official clinical practice guideline of the American thoracic society and infectious disease society of America. *Am J Respir Crit Care Med*. 2019; 200 (7): pe45—e67.
8. Lim WS. Woodhead M. British Thoracic Society. British Thoracic Society adult community acquired pneumonia audit. *Thorax*. 2011; 66: 548—9.
9. Mizgard J. Acute lower respiratory tract infection. *N Eng J Med*. 2008; 358: 716—27.
10. Moldoveanu B, Otmishi P, Jani P, Walker J, Samiento X, Guardiola J et al. Inflammatory mechanism in the lung. *J of Inflamm Research*. 2009; 2:1—11.

11. Shaddock EJ. How and when to use common biomarkers in community acquired pneumonia. *Pneumonia*. 2016; 8—17.
12. Bouchon, A, Dietrich, J, Colonna, M. Cutting Edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrofilis and monocytes. *J of Immuunol*. 2000; 164(10): 4991—5.
13. Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Milena-Abril A. Prognosis of community acquired pneumonia : value triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. *Cytokine*. 2017; 38(3); 17—23.
14. Tintinger GR, Van der Merwe JJ, Fickl R, Rheeder P, Feldman C, Anderson R. Soluble trigerrring expressed on myeloid cells in sputum of patients with community-acquired pneumonia or pulmonary tuberculosis : a pilot study. *Eur J Clin Microbiol Infect Dis*.2012; 31: 73—6.
15. Su L, Liu D, Chai W, Liu D, Long Y. Role of sTREM-1 in predicting mortality of infection : a systematic review and meta-analysis. *BMJ Open*. 2016; 6: e010314.
16. Jedynak M, Siemiakowski A, Mcroczo B, Groblewska M, Milewski R, Szmikowski. Soluble TREM-1 serum can early predict mortality of patients with sepsis, severe sepsis, and septic shock. *Arc Immunol et Therap Exp*. 2018; 66: 299—306.
17. Liang D, Li L, Yan J. Effect of sTREM-1 on prognosis of patients with ventilator-associated pneumonia. *Chin J Emer Med*. 2018; 27(1): 93—8.
18. Alavi-Moghaddam M, Bakhsi H, Razaei B, Khashayar. Pneumonia severity index compared to CURB-65 predicting the outcome of community acquired pneumonia among patients referred to an Iranian emergency. *Braz J Infect Dis*. 2013; 17(2):179—83.
19. Liu, JL, Xu F, Zhou H, Wu XJ, Shi LX, Lu RQ et al. Expanded CURB-65 : a new score system predicts severity of community-acquired pneumonia with superior efficiency. *Scien Repts*.2016; 6(1): 1—7.
20. Shehata SM, Sileem AE, Shahien NE. Prognostic values of pneumonia severity index, CURB-65 and Expanded CURB-65 scores in community acquired

pneumonia in Zagazig University Hospital. Egypt. J of Chest DisTuber.2017; 66(3): 549—55.

21. Efiyanti, Pitoyo CW, Singh G, Koesno S. Uji validasi Expanded CURB-65 sebagai prediktor mortalitas 30 hari pasien pneumonia komunitas di rumah sakit umum pusat nasional cipto mangunkusumo. Indo J Chest.2018; 5(1): 35—42 .
22. World Health Organization (WHO). Top 10 causes of death worldwide 2015. Can access <http://www.who.int/mediacentre/factsheets/fs310/en/>
23. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA et al. Adults hospitalized with pneumonia in the united states: incidence, epidemiology & mortality. Clin Infect Dis. 2017; 65: 1806—12.
24. Laporan Rekam Medis. Padang: RSUP Dr M Djamil, Rekam Medis; 2016.
25. Rider AC, Frazee BW. Community acquired pneumonia. Emerg Med Clin N am. 2018: 665—683.
26. Lanks CW, Musani AL, Hsia DW. Community-acquired pneumonia and hospital acquired pneumonia. Med Clin N Am. 2019: 487—501.
27. Perhimpunan Dokter Paru Indonesia (PDPI). Pneumonia komuniti : pedoman diagnosis dan tatalakasana di Indonesia. 2003.
28. Lutfiyya M, Henley E, Chang L. Diagnosis and treatment of community acquired pneumonia. AM Fam Physician. 2006; 73: 442—50.
29. Balamayooran G, Batra S, Fessler M, Happel K, Jayaseelan S. Mechanism neutrofil accumulation in the lungs against bacteria. Am J of Resp Cell and Mol Biol. 2010; 43: 5—16.
30. Welte T, Chalmers JD, Oletz MW, Aliberti S. Community acquired pneumonia. Eur Resp Mono. 2012; 67: 71—79.
31. Gingras MC, Lapillonne H, Margolin JF. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol 2002; 38(11): 817—24.
32. Mahdy AM, Lowes DA, Galley HF, Bruce JE, Webster NR. Production of soluble triggering receptor expressed on myeloid celss by lipopolysaccharide-stimulated human neutrophils involves de novo protein synthesis. Clin vac immunol. 2006: 492—95.

33. El Bakry SA, Bassyouni IH, El Shaxly R, Abou-Ell Alla AA. Clinical significance of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in patients with rheumatoid arthritis. *The Egypt Rheumato*. 2013; 35: 95—100.
34. Kluckova K, Kozak J, Szaboova K, Rychly B, Svajdler M, Suchankova M et al. TREM-1 and TREM-2 expression on blood monocytes could help predict survival in high grade glioma patients. *Hindawi Media of Inflamm*. 2020: 1—13.
35. Phua J, Koay ES, Zhang D, Tai LK, Boo XL, Lim KC et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. *Eur Respir J*. 2006; 28(4): 695—702.
36. Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papis SA, Giamarellou H et al. Diagnostic value of triggering receptor expressed on myeloid cells-1 and c-reactive protein for patients with lung infiltrates: an observational study. *BMC Infect Dis*. 2010; 10(1): 286—96.
37. Chao WC, Wang CH, Chan MC, Chow KC, Hsu JY, Wu CL. Predictive value of serial measurements of sTREM-1 in the treatment response of patients with community-acquired pneumonia. *J Formos Med Assoc*. 2007; 106(3): 187—95.
38. Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I—currently available biomarkers for clinical use in acute infections. *Ann Intensive Care*. 2013; 3(1): 22.
39. Shi JX, Li JS, Hu R, Li CH, Wen Y, Zheng et al. Diagnostic Value of sTREM-1 in Bronchoalveolar Lavage Fluid in ICU Patients With Bacterial Lung Infections: A Bivariate Meta-Analysis. *PLoS ONE*. 2013; 8(5): 1—9.
40. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. *New Eng J of Med*. 2007; 350(5): 451—58.
41. Grover V, Pantelidis P, Soni N, Takata M, Shah PL, Wells AU et al. A biomarker panel (bioscore) incorporating monocytic surface and soluble TREM-1 has high discriminative value for ventilator-associated pneumonia: a prospective observational study. *PLoS One*. 2014; 9(10): 1—8.

42. Ye W, Hu Y, Zhang R, Ying K. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in lower respiratory tract infections: a meta-analysis. *Resp*. 2014; 19(4): 501—7.
43. Tamaro A, Derive M, Gibot S, Leemans JC, Florquin , Dessing MC. TREM-1 and its potential ligands in non infectious disease: from biology to clinical perspective. *Phar and Theur*. 2017. 81—95.
44. Kouassi KT, Gunasekar P, Agrawal DK, Jadhav GP. TREM-1; Is it a pivotal target cardiovascular disease. *J of Card Dev and Dis*. 2018; 5: 45—61.
45. Jung YS, Park JJ, Hong SP, Kin TI, Kim WH, Cheong JH. Correlation between soluble triggering receptor on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel disease. *J of the Italy Gastro*. 2012; 44(11): 897—903.
46. El-Hewala AE, Soliman SG, Badr E, Esaily HA, Allah EA. Study of plasma of soluble triggering receptor expressed on myeloid cells-1 in rheumatid arthritis and its correlation with disease activity and tumor necrosis factor- α . *Egypt Rheu and Rehab*. 2017; 45:18—24.
47. Ho C, Liao W, Wang C, Lu Y, Huang H, Chen H. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. *Am J Resp Crit Care Med*. 2008; 177: 763—70.
48. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Lewis SA et al. Defining community acquired pneumonia severity on presentation to hospital : an international derivation and validation study. *Thorax*. 2003; 58: 377—82.
49. Suryastri, Medison I, Herman D, Russilawati. Perbandingan Expanded CURB-65 terhadap CURB-65 dan PSI dalam memprediksi luaran pasien pneumonia komunitas. *J Endur*. 2019; 4(3): 608—16.
50. Drent M, Cobben NAM, Henderson RF, Wouters EFM, Van Dieijen-Visser M. Usefulness of lactate dehydorgenase and its isoenzyme indicators of lung damage or inflammation. *Eur Respir J*. 1996. 9: 1736—42.
51. Ewig S, Bauer T, Hasper E, Pizulli L, Kubini R, Luderitz B. Prognostic analysis and predictive value for outcome of hospital-treated community acquired pneumonia. *Eur J Inflam*. 1995. 8: 392—97.

52. Hendy RM, Elawady MA, Abd El Kareem HM. Role of lactate dehydrogenase and other biomarkers in predicting prognosis of community-acquired pneumonia. *Egypt J Bronchol.* 2019; 13: 539—54.
53. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert, PE. Soluble Triggering Receptor Expressed on Myeloid Cells and the Diagnosis of Pneumonia. *New Engl J of Med.* 2004; 350(5): 451—58
54. Silveyra P, Fuentes N, Rivera L. Understanding the Intersection of Environmental Pollution, Pneumonia, and Inflammation: Does Gender Play a Role?. *Intech.* 2018 : 1—32.
55. Quero BG, Fernandez LS, Moyano MG, Garrido IS, Bonilla AG, Crespo BG et al. Difference in community acquired pneumonia according gender. *Eur Resp J.* 2017; 50: PA410.
56. Barbagelata E, Cilloniz C, Dominedo C, Torres A, Nicolini A, Solidoro P. Gender differences in community acquired pneumonia. *Min Medi.* 2020; 111(2): 153—65.
57. Serin DÇ, Pullukçu H, Çiçek C, Sipahi OR, Taşbakan S, Atalay, S. Bacterial and viral etiology in hospitalized community acquired pneumonia with molecular methods and clinical evaluation. *J Infect Dev Ctries.* 2014; 8(4): 510—18.
58. Farida H, Severin JA, Gasem MH, Keuter M, Wahyono H, Van Den Broek P, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae* in pneumonia-prone age groups in Semarang, Java island, Indonesia. *PLoS ONE.* 2015; (1): 1—3.
59. Ramirez J, Wiemken, T, Peyrani, P. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clin Infect Dis.* 2017; 65: 1806-12.
60. Chebib N, Cuvelier C, Maleziux-Picard A, Parent T, Roux X, Fassier T. Pneumonia prevention in the elderly patients : the other sides. *Aging Clin and Exp Res.* 2019: 1—10.
61. Campling J, Jones D, Chalmers JD, Vyse A, Madhava A, Ellsbury G et al. The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England. *Pneumonia.* 2019; (11): 4—11.

62. Chou C, Wang S, Liang C, Chang C, Liu J, Wang I, et al. Risk pneumonia among patients with chronic kidney disease in outpatient and inpatient setting. *Medicien*. 2014; 93(27): 1—4.
63. Richeldi L, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C et al. Triggering receptor expressed on myeloid cells : role in the diagnosis of lung infection. *Eur Resp J*. 2004; 24: 247—50.
64. Tintinger GR, Laubscher C. Soluble triggering receptor expressed on myeloid cells (s-TREM-1) from endotracheal aspirates in critically ill patients : A potential Marker of dynamic inflammatory burden of the lower respiratory tract. *SAJCC*. 2010; 26: 1—10.
65. Siranovic M, Kovac J, Gopcevic S, Kelecic M, Kovac N, Rode B et al. Human soluble TREM-1 : Lung and serum levels in patients with bacterial ventilator associated pneumonia. *Acta Clin Croat*. 2011; 50: 345—49.
66. Rohde G, Radsak MP, Borg I, Buhl R, Schultze-Werninghaus G, Taube C. Levels of Soluble Triggering receptor expressed on Myeloid cells-1 in infectious exacerbation chronic obstructive pulmonary disease. *Resp*. 2012; 83: 133—9.
67. Neto PVS, Carvalho JCS, Pimentel VE, Perez MM, Carmona-Gracia I, Neto NT et al. Prognostic value of sTREM-1 in COVID-9 patients : a biomarker for disease severity and mortality. *medRxiv*. 2020: 1—28.

